REAX · The Real Brokerage, Inc.

Current Thesis

Real REMAX Group's capital-return recovery case requires a weekly close above the broken $18.00 threshold before a weekly close below the September 18 reference close of $16.53. This is a new, low-conviction recovery hypothesis: the September 6 thesis already failed its published $18.00 weekly invalidation at the September 18 close. The company's August 24 repurchase authorization supplies a possible mechanism for recovery, but execution remains unverified.

The life-cycle assessment is an inference: the narrative is dead — the September 18, 2026 weekly close breached the previously published thesis-break condition after the August 24 merger completion. That describes the failed post-merger price structure, not a finding that the combined business cannot succeed. The narrower recovery hypothesis would play out on a weekly close above $18.00 before its new invalidation fires; combined operating performance remains a separate, unresolved test.

Bullish and bearish views on The Real Brokerage, Inc.

The model's bull view on The Real Brokerage, Inc. (REAX), in brief: Revenue growth preceded the combination. The bear view: The published threshold has failed. The adjusted September 18, 2026 close of $16.53 is below the $18.00 weekly invalidation published on September 6. The previous thesis therefore cannot remain open pending the next earnings report. Financing creates a contractual burden. The… Both cases follow in full.

Bull Case

• Revenue growth preceded the combination. Real reported second-quarter 2026 revenue of $700.6 million, up 29.6% year over year, on August 6. That establishes operating growth before the merger, without establishing the combined company's growth rate. Company results release.
• Capital return has board authorization. The company's August 24, 2026 release authorized repurchases of up to $450 million or 25 million shares, with no fixed expiration. The bullish inference depends on subsequent disclosure of actual repurchases; an authorization alone does not establish demand for the shares.

Bear Case

• The published threshold has failed. The adjusted September 18, 2026 close of $16.53 is below the $18.00 weekly invalidation published on September 6. The previous thesis therefore cannot remain open pending the next earnings report.
• Financing creates a contractual burden. The August 24, 2026 merger-financing disclosure specified $550 million of term debt, quarterly principal amortization of 1.875%, and an initial maximum first-lien net leverage ratio of 4.50 times. Repurchase capacity cannot be assessed from the authorization alone without subsequent cash-flow and leverage disclosures.
• Housing turnover weakened again. The National Association of Realtors reported on September 10, 2026 that August existing-home sales fell 2.0% month over month. This is adverse industry evidence, although it does not establish Real REMAX's own transaction growth. NAR existing-home sales.

Setup & Price Structure

The September 18, 2026 adjusted close was $16.53; the shares were down 4.5% over three months, and the 14-day relative strength index (RSI) was 33.1. These observations show weak recent momentum. They do not establish a reversal or a support shelf at $16.53.

For the separate recovery hypothesis, $16.53 is explicitly the latest reference close used as a prospective weekly boundary. The $18.00 recovery condition is the failed threshold from the September 6 publication. A subsequent weekly close below $16.53 would end this narrower case; it would not alter the earlier thesis's recorded failure.

Benzinga coverage clustered around merger completion and the repurchase announcement on August 24–25, 2026, including company-specific headlines and market roundups. That measures coverage concentration, not investor positioning. No current short-interest, ownership-flow or moving-average measurement establishes crowding; the available observations are insufficient to infer forced selling or repurchase activity.

Catalyst Calendar (next 30 days)

• 2026-10-13 — September existing-home sales. NAR's published calendar identifies the next completed-sales report. It supplies a dated comparison with the August decline reported on September 10, without resolving company-specific integration performance. NAR release schedule.
• 2026-10-20 — September pending-home sales. NAR schedules its next contract-signing report for this date. The release provides another housing-demand observation; it does not establish Real REMAX's revenue or margins. NAR release schedule.

Management's August 6 communication deferred the combined baseline and preliminary 2027 figures to the November 2026 third-quarter call. An exact November reporting date is unverified as of September 20, so no specific day is asserted. Repurchase execution, integration costs and the combined outlook remain the company disclosures needed to assess the operating case.

What Would Change Our Mind

Failure to retain the September 18 reference close would break the new recovery hypothesis: a weekly close below $16.53 is its observable invalidation. A weekly close above $18.00 occurring first would satisfy the narrowly defined price-recovery case. Neither outcome would establish whether the August 24 combination improves operating performance.

Actual repurchases disclosed under the August 24 authorization would substantiate the capital-return mechanism. A third-quarter report showing no repurchases would contradict that mechanism for the reported period; missing disclosure would leave it unresolved rather than prove that no repurchases occurred.

Correlation Notes

This remains a single-name integration case; no dated peer-return sample establishes a group-driven recovery. NAR's September 10 housing report supplies industry context, not a measured equity correlation.

The August 24 credit terms create direct contractual rate exposure: the term-loan pricing references the secured overnight financing rate (SOFR), with a 3.00% floor and a 5.50% spread. That establishes a financing channel, but the available evidence does not quantify the stock's sensitivity to interest rates.